REV-ERB comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
=== Category:EC 2.2 (transfer aldehyde or ketone groups) === Category:EC 2.2.1 Transketolase EC 2.2.1.1 Transaldolase EC 2.2.1.2 Acetolactate synthase EC 2.2.1.6 2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase EC 2.2.1.9
Hours after Palacios' statement, Free Peru's General Secretary Vladimir Cerrón said "When you lose faith in your militancy, you force yourself to look for strength with the mercenaries." Cerron also quoted Borges by saying "traitors are reliable because they never change." Afterward, El Comercio released a paper claiming that the Free Peru caucus voted as a split group nearly 50% of the time. On 29 November 2021, Vladimir Cerrón announced that Free Peru would hold an extraordinary national assembly on 5 December 2021, to determine the party's stance on the impeachment motion, the government, and other topics. On 6 December 2021, Free Peru concluded its extraordinary national assembly by announcing that it would vote unanimously against impeachment. Free Peru stated that it has "serious discrepancies" with the "caviar" government of Castillo, but also accused the pro-impeachment movement of being fascist and anti-democratic. Additionally, Free Peru also reaffirmed that it considered Cuba, Venezuela, and Bolivia to have democratic governments.
Cl3C−S−Cl + H2O → Cl−S−C(=O)−Cl + 2 HCl The compound, being bifunctional, has been used for the preparation of several heterocycles including oxathiazol-2-ones, oxathialones, and oxathiazoles. Treatment with formamides gives dithiazolidinediones (also known as dithiasuccinoyl, or DTS). Relevant to amino acid chemistry, ethylthionocarbamates react with chlorocarbonylsulfenyl chloride to give DTS derivatives:
== Genetics == The human OPRK1 gene is located on chromosome 8 and comprises four exons separated by three introns, spanning approximately 25 kilobases. The gene utilizes at least three transcription initiation sites, generating mRNAs with 5′-UTRs of 215–299 nucleotides, with the predominant isoform containing 238 nucleotides of 5′-UTR sequence. The exon-intron organization is conserved between human, mouse, and rat OPRK1 genes.
Sources: en.wikipedia.org
=== Quantification in cow's milk cheese via real-time polymerase chain reaction assay === In 2017, there was a study involving the development of a real-time polymerase chain reaction (qPCR) assay for quantifying Lactobacillus delbrueckii subsp. bulgaricus as well as Streptococcus thermophilus in cow's milk cheese. The goal of this study was to create a way to identify and quantify Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus, two lactic acid producing species crucial to the fermentation and ripening of cheese, in a timely manner through the use of qPCR. Two assays using lacZ gene targeting PCR primers resulted from this study and were deemed compatible with the two lactic acid bacteria (LAB) species. This allowed for the direct quantification of Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus in cheese produced from unpasteurized cow's milk.
Multiple types of internal border controls exist in the United States. While the American territories of Guam and the Northern Mariana Islands follow the same visa policy as the mainland, together, they also maintain their own visa waiver programme for certain nationalities. Since the two territories are outside the customs territory of the United States, there are customs inspections when travelling between them. The rest of the U.S. American Samoa has its own customs and immigration regulations, thus travelling between it and other American jurisdictions involves both customs and immigration inspections. The Virgin Islands are a special case: they fall within the American immigration zone and follow American visa policy, but are a customs-free territory. As a result, there are no immigration checks between the two, but travellers arriving in Puerto Rico or the American mainland directly from the Virgin Islands are subject to border control for customs inspection. The United States also maintains interior checkpoints, similar to those maintained by Bhutan, along its borders with Mexico and Canada, subjecting people to border controls even after they have entered the country. The Akwesasne nation; with territory in Ontario, Quebec, and New York; features several de facto internal border controls.
phosphatase Any of a class of enzymes that catalyze the hydrolytic cleavage of a phosphoric acid monoester into a phosphate ion and an alcohol, e.g. the removal of a phosphate group from a nucleotide via the breaking of the ester bond connecting the phosphate to a ribose or deoxyribose sugar or to another phosphate, a process termed dephosphorylation. The opposite process is performed by kinases.
The insulin/IGF/relaxin family is a group of evolutionarily related proteins which possess a variety of hormonal activities. In humans, these proteins are divided into two subsets: 1) insulin and insulin-like growth factors 2) relaxin family peptides:
The dress uniform had blue or green breeches with broad, coloured stripes in the host colour, which were often worn with the service jacket. While most Cossacks served as cavalry, several of the larger hosts had infantry and artillery units. Three regiments of Cossacks formed part of the Imperial Guard, as well as the Konvoi—the tsar's mounted escort. The Imperial Guard regiments wore tailored, government-issue uniforms, which were colourful and elaborate. For example, the Konvoi wore scarlet cherkesskas, white beshmets, and red crowns on their fleece hats. The Guard Cossacks of His Majesty and the Ataman's Guard Cossacks, both drawn from the Don Host, wore red, and light blue, coats respectively. The Combined Cossack Guard Regiment, comprising representative detachments from each of the remaining hosts, wore red, light blue, crimson, or orange coats, according to squadron.
Sources: en.wikipedia.org
Brown bread, in contrast to white bread, is bread made with significant amounts of whole grain flours, usually wheat sometimes with corn and or rye flours. In some countries brown breads often get their characteristic dark color from ingredients such as molasses or coffee. In Canada, the UK, Ireland and South Africa, it is a blend of white flour and whole wheat flour. Wholemeal bread within the UK must be made solely from whole wheat flour. In New England and the Maritimes, brown bread is bread sweetened with molasses.
== Success rate == Candidates for a new drug to treat a disease might, theoretically, include from 5,000 to 10,000 chemical compounds. On average about 250 of these show sufficient promise for further evaluation using laboratory tests, mice and other test animals. Typically, about ten of these qualify for tests on humans. A study conducted by the Tufts Center for the Study of Drug Development covering the 1980s and 1990s found that only 21.5 percent of drugs that started Phase I trials were eventually approved for marketing. In the time period of 2006 to 2015, the success rate was 9.6%. The high failure rates associated with pharmaceutical development are referred to as the "attrition rate" problem. Careful decision making during drug development is essential to avoid costly failures. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well-designed, dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data.
== Markets == Fine chemicals are used as starting materials for specialty chemicals. The latter are obtained either by direct formulation or after chemical/biochemical transformation of intermediates to active substances. Life sciences, primarily pharmaceutical, agrochemical and food and feed industries, are the main consumers of fine chemicals.
=== Opioid receptors === A genetic basis for the efficacy of opioids in the treatment of pain has been demonstrated for several specific variations, but the evidence for clinical differences in opioid effects is not clear. There is an estimated 50% genetic contribution to opioid use disorder. The pharmacogenomics of the opioid receptors and their endogenous ligands have been the subject of intensive activity in association studies. These studies test broadly for a number of phenotypes, including opioid dependence, cocaine dependence, alcohol dependence, methamphetamine dependence/psychosis, response to naltrexone treatment, personality traits, and others. Major and minor variants have been reported for every receptor and ligand coding gene in both coding sequences, as well as regulatory regions. Research on endogenous opioid receptors has focused around the OPRM1 gene, which encodes the μ-opioid receptor, and the OPRK1 and OPRD1 genes, which encode the κ and δ receptors, respectively. Newer approaches shift away from analysis of specific genes and regions to screen the entire genome. These GWAS studies have yielded a number of implicated genes, although many of them code for seemingly unrelated proteins in processes such as cell adhesion, transcriptional regulation, cell structure determination, and RNA, DNA, and protein handling/modifying.
Norbinaltorphimine (nor-BNI or nBNI) is an opioid receptor antagonist used in scientific research. It is a highly selective inverse agonist for the κ-opioid receptor. In animals, nor-BNI blocks the effects of κ-opioids with a slow onset and an exceptionally long duration of action (up to several months). It produces antidepressant-like and anxiolytic-like effects in animal models.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.